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Introduction
The Pax gene family defi  nes an evolutionary conserved group 
of transcription factors that play critical roles during organo-
genesis and tissue homeostasis (Chi and Epstein, 2002; Robson 
et al., 2006). Nine Pax proteins have been described in mammals, 
where the presence of the paired box DNA binding domain 
is a common feature. The family is further subgrouped by the 
presence of an octapeptide motif and the presence, absence, or 
truncation of a homeodomain region.
Pax3 and Pax7 are two closely related family members 
(Bober et al., 1994; Goulding et al., 1994; Tajbakhsh et al., 
1997; Chi and Epstein, 2002; Robson et al., 2006) that are 
involved in the specifi  cation and maintenance of skeletal mus-
cle progenitors. Genetic analyses in mice showed that Pax3 is 
critical for delamination and migration of muscle precursors 
from the somites to the limbs (Bober et al., 1994; Goulding 
et al., 1994; Tajbakhsh et al., 1997). Pax7
−/− mice have no 
gross defects in muscle formation. However, in the absence of 
Pax7, adult skeletal muscles are completely devoid of satellite 
cells (Seale et al., 2000; Oustanina et al., 2004), which are 
thought to represent the stem cell compartment responsible 
for postnatal muscle growth and regeneration. Accordingly, 
Pax7-null mice exhibit reduced muscle growth, marked mus-
cle wasting, and an extreme deficit in muscle regeneration 
after acute injury (Seale et al., 2000; Kuang et al., 2006). De-
spite these differences, both Pax3 and Pax7 appear to mark 
a population of muscle progenitors (Pax3
+/Pax7
+ cells) in 
the dermomyotome of embryonic somites (Ben-Yair and 
Kalcheim, 2005; Gros et al., 2005; Kassar-Duchossoy et al., 
2005; Relaix et al., 2005). Pax3
+/Pax7
+ cells proliferate and 
persist throughout embryonic and fetal development and are 
proposed to be the cellular origin for satellite cells. Pax3 ex-
pression is down-regulated in satellite cells before birth and 
appears to be confined to a subpopulation of satellite cells 
in specifi  c muscle groups (Kassar-Duchossoy et al., 2005; 
Relaix et al., 2006). Thus, cumulative evidence supports dis-
tinct roles for Pax3 and Pax7 during myogenesis and a critical 
requirement for Pax7 in satellite cell specifi  cation, survival, 
and potentially, self-renewal (Seale et al., 2000; Olguin and 
Olwin, 2004; Oustanina et al., 2004; Zammit et al., 2004; 
Kuang et al., 2006; Shinin et al., 2006).
In adult muscle, quiescent satellite cells express Pax7, 
whereas expression of Myf5 and MyoD is low or nondetect-
able (Yablonka-Reuveni and Rivera, 1994; Cornelison and 
Wold, 1997; Seale et al., 2000). Pax7 persists at lower levels 
in recently activated, proliferating satellite cells and is rapidly 
down-regulated in cells that commit to terminal differentiation 
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(Olguin and Olwin, 2004; Zammit et al., 2004). In culture, Pax7 
appears to be up-regulated and persists in a small population of 
myogenic cells that down-regulate MyoD expression. This sub-
population remains undifferentiated and mitotically inactive, 
resembling a quiescent satellite cell (Olguin and Olwin, 2004; 
Zammit et al., 2004). We have previously shown that Pax7 over-
expression recapitulates these events in proliferating myogenic 
cells (Olguin and Olwin, 2004). Moreover, ectopic expression 
of Pax7 can effi  ciently repress the MyoD-dependent conversion 
of mesenchymal cells to the muscle lineage (Olguin and Olwin, 
2004). Although this is evidence for a functional relationship 
between Pax7 and the MyoD family of transcription factors, 
the exact nature of this relationship is controversial (Olguin and 
Olwin, 2004; Oustanina et al., 2004; Seale et al., 2004; Relaix 
et al., 2006; Zammit et al., 2006).
Here, we attempted to delineate the molecular mecha-
nisms involved in Pax7-mediated repression of MyoD function 
and myogenic progression. Our data indicate that Pax7 blocks 
myogenesis independently of its transcriptional activity, by a 
mechanism involving regulation of MyoD protein stability. Simi-
larly, myogenin, but not MyoD, appears to regulate Pax7 function 
by affecting Pax7 levels. These results provide evidence sup-
porting the existence of a reciprocal inhibition between Pax7 and 
the muscle regulatory factors (MRFs). Our data suggest that this 
mechanism may function to regulate the decision of an activated 
satellite cell to proliferate, commit to terminal differentiation, or 
reacquire a quiescent state.
Results
Pax7 represses myogenesis via inhibition 
of MyoD activity
During myogenic differentiation, Pax7 up-regulation is ob-
served in cells that remain undifferentiated and down-regulate 
MyoD expression (Olguin and Olwin, 2004; Zammit et al., 2004), 
which is reminiscent of the reserve cell phenotype (Yoshida et al., 
1998). Furthermore, overexpression of Pax7 down-regulates 
MyoD in satellite cells and myogenic cells lines, preventing 
terminal differentiation and cell cycle progression (Olguin and 
Olwin, 2004). Pax7 also inhibits MyoD-induced myogenic 
conversion of C3H10T1/2 cells (Olguin and Olwin, 2004), 
suggesting that Pax7-mediated inhibition of muscle differen-
tiation occurs before induction of myogenin expression. To 
determine whether these effects are regulated at the transcrip-
tional level, we asked if Pax7 differentially affects MyoD and 
myogenin transcriptional activity. We fi  rst assessed the ability 
of MyoD and myogenin to activate transcription from a lucif-
erase reporter driven by the proximal regulatory region of the 
myogenin gene (myogenin-Luc; Fig. 1 A), in the presence or 
the absence of Pax7. Ectopically expressed MyoD activates 
the myogenin-Luc reporter gene >5,000-fold during the myo-
genic conversion of C3H10T1/2 cells, whereas ectopically 
  expressed myogenin activates the reporter gene >700 fold 
(Fig. 1 A). Cotransfection of Pax7 represses MyoD transcrip-
tional activity up to 90% in a dose-dependent manner (Fig. 1 B). 
However, myogenin activity was substantially less affected by 
Pax7 coexpression (approximately threefold repression at the 
highest Pax7 dose) than MyoD (Fig. 1 B). These data suggest 
that Pax7-dependent repression of myogenesis is specific 
for MyoD.
We hypothesized that inhibition of MyoD function could 
arise via competition of Pax7 and MyoD for binding to common 
DNA targets. Thus, MyoD transcriptional activity on a non-
canonical regulatory element should be insensitive to Pax7 repres-
sion. We tested this possibility by changing the DNA binding 
specifi  city of MyoD using a Gal4-MyoD fusion protein and 
Figure 1.  Differential effects of Pax7 on MyoD and myogenin activity. 
(A, top). Schematic representation of the myogenin-Luc reporter (see 
Materials and methods). (bottom) Myogenin-Luc reporter gene is robustly 
activated by both MyoD (>5,000-fold) and myogenin (>700-fold). Pax7 
has no effect on basal activity. Basal reporter activity was normalized to 1. 
(B) Pax7 coexpression differentially affects MyoD (4.8- ± 0.17- and 
16.4- ± 1.9-fold repression at 1:1 and 1:2 molar ratio, respectively; 
black bars) versus myogenin (1.9- ± 0.15- and 2.8- ± 0.5-fold repres-
sion, respectively; white bars) transcriptional activity. (C) Transcriptional 
activity of a Gal-MyoD fusion protein (activation of the Gal4-luc reporter 
gene; schematic) is inhibited by Pax7 coexpression (13.6- ± 2.4-fold re-
pression at 1:2 Gal4-MyoD/Pax7 molar ratio). Gal-VP16 transcriptional 
activity is considerably less sensitive to Pax7 coexpression (3.5- ± 0.06-
fold repression). In B and C, maximum reporter activity was normalized 
to 1. Asterisks indicate that mean values are representative of at least 
three independent experiments. Error bars indicate standard deviation. 
(D) Binding of puriﬁ  ed MyoD and E47 (E47N) to a DNA target is not dis-
rupted by in vitro translated Pax7 protein (right). MCK-REbox indicates 
right E-Box of the muscle creatine kinase promoter ◀, E47N–MyoD–DNA 
complex; ◆, MyoD–DNA complex; ○, E47N–DNA complex. RRL, rabbit 
reticulocyte lysate. Arrowheads indicate the expected Pax7, MyoD, and 
E47 bands according to molecular weight. (left) Control in vitro translation 
for Pax7 expression.PAX7-MRFS CROSS-REGULATION IN MYOGENESIS • OLGUIN ET AL. 771
determining the activation of a Gal4-Luc reporter gene (Fig. 1 C). 
Surprisingly, Pax7 was able to repress the activity of the fusion 
protein (Fig. 1 C). The inhibition of the Gal4-MyoD activity was 
quantitatively equivalent to that observed for wild-type MyoD 
(Fig. 1 C). This effect is specifi  c for MyoD because a constitu-
tive activator (Gal4-VP16) shows a greatly reduced sensitivity 
to cotransfection of Pax7 (Fig. 1 C), suggesting that the ability 
of Pax7 to repress MyoD transcriptional activity is unlikely to 
refl  ect a competitive binding to a common DNA target. This is 
further supported by the inability of Pax7 to either bind directly 
to a MyoD target sequence (MCK-REbox) or disrupt the binding 
of MyoD, E47, or MyoD-E47 dimers to DNA in electrophoretic 
mobility shift assays (EMSAs; Fig. 1 D). Consequently, we 
envision at least two mechanisms whereby Pax7 could inhibit 
MyoD activity: (1) regulating transcription of additional genes 
required for MyoD function or (2) a nontranscriptional mecha-
nism, such as competition for a common interaction partner. To 
determine the contribution of Pax7 transcriptional activity to 
the inhibition of myogenesis, we performed deletion analysis of 
domains required for this function in Pax7 and tested the ability 
of the mutant proteins to repress MyoD activity during myogenic 
conversion of C3H10T1/2 cells.
The Pax7 homeodomain is critical 
for the repression of MyoD function
A series of Pax7-deletion mutants were generated (see Materials 
and methods) containing a myc-tag epitope followed by an 
NLS inserted at the N terminus of each mutant construct (Fig. 
2 A, top). A prior set of mutants lacking the exogenous NLS ex-
hibited cytoplasmic mislocalization and high variability in pro-
tein expression, suggesting major differences in protein stability 
(unpublished data). The mutant proteins used in subsequent 
assays (myc-NLS) were expressed at relatively similar levels 
(Fig. 2 A, bottom), with the exception of the ∆C mutant, which 
showed higher levels of protein expression at equivalent 
amounts of transfected expression vector (Fig. 2 A, bottom). 
This difference appears to be related to enhanced protein sta-
bility compared with other mutant products (unpublished data). 
The ability of each Pax7-deletion mutant to repress myogenic 
conversion of C3H10T1/2 cells induced by ectopic expression 
Figure 2.  The Pax7 homeodomain regulates MyoD activity. (A, top) Schematic representation of Pax7 functional domains and deletion mutants. FL, full 
length; PB, paired-box domain; HD, Hox/Homeodomain; TAD, transactivation domain. Black bars indicate octapeptide, ovals indicate myc-tag epitope, 
and gray boxes indicate SV40 T-antigen NLS. (bottom) Expression of Pax7 mutants (arrowheads) was analyzed by Western blots in C3H10T1/2 cells. 
Tubulin was used as loading control. (B and C) Deletion of the Pax7 paired-box domain (∆N; B) or transactivation domain (∆C; B) has no signiﬁ  cant effects 
on repression of MyoD transcriptional activity (left) or on myogenic differentiation of C3H10T1/2 cells (MyHC expression; right) mediated by Pax7. Dele-
tion of the homeodomain (∆HD; C) impairs Pax7-mediated inhibition of MyoD transcriptional activity (left) and myogenic differentiation in C3H10T1/2 
cells (right). Expression of either PB (∆OC) or TAD (∆NHD) domains alone have no signiﬁ  cant effects on MyoD activity (C). (D) Effects of Pax7-deletion 
mutants on myogenin transcriptional activity. Maximum reporter activity was normalized to 1 in B and D. (E) Analysis of the transcriptional activity of Pax7 
and Pax7-deletion mutants (on the 6xPRS9-luc reporter gene) during myogenic conversion of C3H10T1/2 cells. Basal reporter activity was normalized to 1. 
Asterisks indicate that data are representative of at least two independent experiments. Error bars indicate standard deviation. Bars, 12 μm.JCB • VOLUME 177 • NUMBER 5 • 2007  772
of MyoD was then evaluated. Pax7 mutants lacking either the 
paired-box or the transactivation domains repressed MyoD 
  activity (Fig. 2 B, left), resembling the effect of the full-length 
Pax7. These fi  ndings correlated with a severe reduction in both 
myotube formation and expression of myosin heavy chain 
(MyHC), a marker of terminal differentiation (Fig. 2 B, right). 
In contrast, deletion of the homeodomain region abolished the 
effect of Pax7 on MyoD activity (Fig. 2 C, left) and failed to 
block myogenic differentiation (Fig. 2 C, right). Expression of 
a deletion mutant containing only the homeodomain and trans-
activation domain is suffi  cient to repress myogenic conversion 
of C3H10T1/2 cells, preventing terminal differentiation (Fig. 2 B). 
Interestingly, this mutant appeared more potent than the full-
length Pax7 protein (Fig. 2 B). Ectopic expression of the N ter-
minus plus the paired-box domain or the transactivation domain 
alone had no considerable effect on MyoD activity (Fig. 2 C). 
Together, these data suggest a critical role for the Pax7 homeo-
domain in repressing myogenesis and inhibiting MyoD func-
tion. This effect appears specifi  c for MyoD, as neither wild-type 
Pax7 protein nor the deletion mutants had substantial effects 
on myogenin transcriptional activity (Fig. 2 D). To further de-
termine whether inhibition of MyoD activity requires Pax7-
dependent transcription, we analyzed the transcriptional activity 
of Pax7 and Pax7 mutants on a reporter gene driven by a regula-
tory sequence derived from the Drosophila even-skipped gene 
(Chalepakis et al., 1991; Bennicelli et al., 1999) containing both 
paired-box and homeodomain binding sites (6xPRS9-Luc). 
  Unexpectedly, we detected only weak Pax7-dependent activation 
of the reporter gene under conditions that repressed MyoD 
activity (Fig. 2 E, left). However, the Pax-dependent reporter 
gene can be activated by full-length Pax7 under proliferation 
conditions (Fig. 2 E, right). As expected, deletion of either the 
paired-box or the transactivation domain abolished Pax7 tran-
scriptional activity (Fig. 2 E). Interestingly, deletion of the 
homeodomain region, required for repression of MyoD activity, 
increased Pax7 transcriptional activity (Fig. 2 E; both under 
proliferation and differentiation conditions). This is in agree-
ment with previous studies showing a cis-acting transcription 
repression activity for this domain in Pax7 (Bennicelli et al., 
1999). These observations indicate that the ability to repress 
MyoD activity does not correlate with active Pax7-dependent 
transcription, suggesting that MyoD protein could be regulated 
by Pax7 protein interactions.
Pax7 expression affects MyoD 
protein stability
Prompted by these observations, we asked if MyoD protein 
levels were affected by ectopic expression of Pax7. Western 
blot analyses of myogenic-converted C3H10T1/2 cell lysates 
revealed that inhibition of MyoD transcriptional activity and 
terminal differentiation correlated with changes in the levels 
of MyoD protein (Fig. 3 A, top). Full-length Pax7 (FL) or a 
Pax7 mutant that represses myogenesis (∆N) reduced MyoD 
protein levels upon cotransfection, whereas a Pax7 mutant that 
does not repress myogenesis (∆HD) had no effect on MyoD 
levels (Fig. 3 A, top). These changes appear specifi  c for MyoD, 
as the levels of Pax7 protein were consistent with the amount 
of expression plasmid added to the cells (Fig. 3 A, bottom). 
Thus, MyoD protein stability appears specifically affected by 
coexpression with Pax7 and Pax7 mutants that inhibit myo-
genic differentiation.
MyoD is subject to regulation through proteasome-
dependent degradation (Abu Hatoum et al., 1998; Song et al., 
1998; Tintignac et al., 2000; Floyd et al., 2001; Lingbeck et al., 
2003; Lingbeck et al., 2005; Sun et al., 2005); thus, we asked 
if this pathway was involved in down-regulating MyoD pro-
tein upon Pax7 coexpression. Loss of MyoD protein after the 
switch to differentiation media in C3H10T1/2 cells expressing 
both MyoD and Pax7 can be detected clearly by 24 h (Fig. 3 B, 
lane 3). Treatment with the proteasome inhibitor MG132 pre-
vented loss of MyoD protein and rescues MyoD to control levels 
(Fig. 3 B, lanes 2 and 1, respectively). Interestingly, MyoD 
stability is affected by Pax7 coexpression in C3H10T1/2 only 
upon a switch to differentiation conditions, as we detected no 
difference in MyoD levels in the presence or absence of Pax7 
when cultures were maintained in proliferation media (Fig. 
3 B, lanes 4–7). This observation indicates that MyoD deg-
radation does not occur via nonspecifi  c effects derived from 
Pax7 overexpression. Most important, proteasome-mediated 
protein degradation also contributes to MyoD down-regulation 
induced by Pax7 overexpression in adult primary myoblasts 
(Olguin and Olwin, 2004), as MG132 treatment partially res-
cues MyoD expression under these conditions (Fig. 3 C). The 
inability of MG132 to fully rescue MyoD protein levels in 
adult myoblasts could be due to a decrease in transcription 
of the endogenous MyoD gene caused by down-regulation of 
MyoD protein.
We expected that rescuing MyoD protein levels would 
rescue its transcriptional activity. Interestingly, MyoD function 
was not restored upon proteasome inhibition, as MG132 treat-
ment did not rescue MyoD-dependent activation of the myogenin-
luc reporter in the presence of Pax7 (Fig. 3 D), even when robust 
nuclear coexpression of both transcription factors was observed 
under these conditions (Fig. 3 E). This finding suggests that 
additional events are involved in Pax7-dependent regulation of 
MyoD activity.
Myogenin can negatively regulate 
Pax7 expression
Initial events in myoblast differentiation include permanent 
withdrawal from the cell cycle and induction of myogenin fol-
lowed by induction of muscle-specifi  c genes. Along with others, 
we have shown that myogenin and Pax7 expression is mutually 
exclusive, whereas Pax7 is retained (and up-regulated) only in a 
small population of cells that escape differentiation and down-
regulate MyoD expression (Olguin and Olwin, 2004; Zammit 
et al., 2004). In light of our new observations, we asked if up-
regulation of myogenin controls Pax7 protein levels. Western 
blot analysis of C3H10T1/2 cell lysates cotransfected with 
myogenin and Pax7 revealed a reduction in Pax7 protein when 
compared with Pax7 levels upon cotransfection with MyoD 
(Fig. 4 A, left; compare lanes 3 and 4). Interestingly, myogenin 
is also considerably reduced upon Pax7 coexpression (Fig. 4 A, 
left), suggesting a reciprocal effect on relative protein levels. PAX7-MRFS CROSS-REGULATION IN MYOGENESIS • OLGUIN ET AL. 773
As observed previously for MyoD, myogenin reduction under 
these conditions involves proteasome-dependent protein degra-
dation, as treatment with MG132 blocks myogenin loss (Fig. 4 A, 
right). Interestingly, MG132 treatment also blocks Pax7 reduc-
tion when myogenin is coexpressed (Fig. 4 A, right). Although 
the levels of Pax7 and myogenin appear to be reciprocally 
affected, Pax7 and myogenin are not coexpressed in adult 
myoblasts (in mice and humans), indicating that these observa-
tions may refl  ect complex population dynamics inherent in an 
asynchronous population of cells undergoing terminal differen-
tiation. To defi  nitively determine whether Pax7 and myogenin 
are coexpressed during the early stages of muscle differentia-
tion, we used the MM14 satellite cell line, where cells can be 
synchronized at M/G1 by mitotic shake-off (Clegg et al., 1987; 
Kudla et al., 1998; Jones et al., 2005). When induced to differen-
tiate, synchronized MM14 cells express muscle-specifi  c genes 
within 6–12 h and begin fusion into multinucleated myotubes by 
12–15 h, providing a useful assay for cell cycle–specifi  c events 
associated with terminal differentiation (Clegg et al., 1987; Kudla 
et al., 1998; Jones et al., 2005). Synchronized MM14 cells were 
allowed to adhere for 8–10 h in the presence of growth medium 
and then cultured in differentiation medium for various periods 
of time (Fig. 4 B). We observed that Pax7 expression persists in 
a large fraction of the cell population until 12 h after differentia-
tion induction (Fig. 4 B, left). As expected, myogenin protein 
was detectable by 8 h after induction of differentiation, reaching 
a maximum at 21 h (Fig. 4 B, middle). Between 8 and 12 h of 
differentiation, Pax7 and myogenin proteins were largely co-
expressed within the same cell population, as 85.5 ± 1.2% (8 h) 
and 82.2 ± 5.2% (12 h) of the myogenin
+ cells showed robust 
expression of both markers, indicating that myogenin protein 
accumulates in Pax7
+ cells (Fig. 4 B, right). Coexpression of 
Pax7 and myogenin is transient because 9 h later (21 h in differ-
entiation medium) the percentage of myogenin
+ cells reached 
a maximum, whereas the percentage of Pax7
+ cells dropped to 
a minimum (Fig. 4 B, middle and left, respectively). At this time 
point, expression of both Pax7 and myogenin becomes mutually 
exclusive, as the percentage of Pax7
+/myogenin
+ cells decreases 
to 7 ± 1.9%. By 30 h, percentages of myogenin
+ and Pax7
+ cells 
have not changed substantially (>80 and <17%, respectively), 
but we could no longer detect cells that were positive for both 
Pax7 and myogenin.
Figure 3.  MyoD protein stability is affected by Pax7. (A) Western blots from C3H10T1/2 cell lysates normalized to equivalent levels of protein (lysate 
aliquots from a representative experiment equivalent to those used in Fig. 2, B and C) were probed for MyoD upon coexpression with Pax7, ∆N, and ∆HD 
Pax7-deletion mutants (top). Relative levels of Pax7 and Pax7 mutants were monitored (using anti-Pax7 and anti–myc-tag antibodies, respectively) in the 
same extracts (bottom). (B, left) MyoD protein is recovered to control levels (lane 1) after incubation with MG132 (lane 2) even in the presence of Pax7 
(compare lanes 2 and 3). Incubation with DMSO has no effect on MyoD levels in the presence of Pax7 (lane 3, control). (bottom) Quantiﬁ  cation of lanes 1–3. 
(right) MyoD levels are unaffected by Pax7 coexpression under proliferation conditions (compare lanes 4 and 5 to 6 and 7, respectively). (C) MG132 treat-
ment results in partial rescue of MyoD protein (yellow arrowheads) in Pax7-overexpressing adult primary myoblasts (compare to DMSO control; white 
arrowheads). Bar, 10 μm. (D) MyoD transcriptional activity in C3H10T1/2 cells is not recovered by proteasome inhibition (tested as in Fig. 2 A). Error 
bars indicate standard deviation. Basal reporter activity was normalized to 1. (E) MG132 treatment results in high levels of MyoD and Pax7 coexpression 
in the majority of transfected C3H10T1/2 cells (white arrows). In control (DMSO) treated cells, only high levels of Pax7 (arrowheads) or MyoD (asterisks) 
can be detected in single cells. Bar, 12 μm.JCB • VOLUME 177 • NUMBER 5 • 2007  774
The change in the Pax7/myogenin ratio during myo-
genic differentiation suggests that accumulation of myogenin 
protein could down-regulate Pax7. Indeed, we observed a re-
duction in Pax7 protein levels upon ectopic myogenin expres-
sion in MM14 myoblasts, even under proliferation conditions 
(Fig. 4 C; nondetectable Pax7 in >96% of transfected cells). If 
myogenin expression is responsible for reducing Pax7 protein, 
forced loss of myogenin under differentiation conditions should 
result in the persistence of Pax7 expression. To test this idea, 
we attempted to knock down myogenin through RNAi. Because 
siRNA transfection in MM14 myoblasts is ineffi  cient and thus 
cannot provide a quantitative assessment for the extent of myogenin 
reduction, we initially tested the effi  cacy of myogenin-specifi  c 
siRNAs in C3H10T1/2 cells ectopically expressing MyoD. As 
determined by Western blot analysis, maximum myogenin knock-
down (>120-fold) was obtained at all doses tested (Fig. 4 D). 
This effect appears to be specifi  c because MyoD expression was 
not affected under the same conditions (Fig. 4 D, right) and myo-
genin protein remained unaffected in the presence of a non  specifi  c 
control siRNA (Fig. 4 D). RNAi-mediated down-regulation 
of myogenin prevented the loss of Pax7 protein (high Pax7 sig-
nal in ≥60% of total transfected cells) in MM14 myoblasts 
(Fig. 4 E). As shown previously, control siRNA had no signifi  -
cant effect on myogenin (Fig. 4 E) or Pax7 protein (not depicted). 
These data support the hypothesis that Pax7 levels are nega-
tively regulated by myogenin in cells undergoing commitment 
to terminal differentiation.
We then asked whether the rapid loss of Pax7 during com-
mitment to differentiation in MM14 cells involved proteasome 
activity. Mitotically synchronized MM14 myoblasts were in-
duced to differentiate for 15 h and treated with DMSO (control) 
or the proteasome inhibitor MG132 for additional 6 h (Fig. 4 F). 
Figure 4.  Myogenin negatively regulates Pax7 expression. (A, left) Western blots from C3H10T1/2 cell lysates expressing MyoD, myogenin, and Pax7 
reveal reduction of both myogenin and Pax7 levels upon coexpression. (middle) Quantiﬁ  cation of lanes 2–4 for myogenin (top) and Pax7 (bottom) abun-
dance, respectively. (right) Proteasome inhibition increases levels of myogenin and Pax7 affected by coexpression. (B) Analysis of Pax7 and myogenin ex-
pression in mitotically synchronized MM14 myoblasts during commitment to terminal differentiation (schematic). At the indicated times, cells expressing 
either Pax7 (white bars) or myogenin (black bars) were independently scored and plotted as a percentage of the total population. Cells coexpressing both 
Pax7 and myogenin (gray bars) are plotted as the percentage of Pax7
+ cells in the myogenin
+ subpopulation. (C) Ectopic expression of myogenin down-
regulates Pax7 (96.6 ± 1.3% of transfected cells are Pax7
−; yellow arrowheads) in MM14 myoblasts under growth conditions. Data are representative of 
three experiments. (D, left) Endogenous myogenin induction in C3H10T1/2 cells (by MyoD forced expression) is efﬁ  ciently down-regulated by RNAi, as 
monitored by Western blot. (right) Quantiﬁ  cation of myogenin abundance in the presence of speciﬁ  c or control (ctrl) siRNAs. Inset shows that MyoD protein 
levels are unaffected. (E) RNAi-mediated down-regulation of myogenin (no detectable myogenin in 60 ± 12.7% of transfected cells; middle and bottom) 
  results in retention of Pax7 expression in differentiating cells (high Pax7 expression in 64.3 ± 18.7% of total transfected cells; bottom, white arrowheads). 
Control siRNA has no effect on myogenin (high myogenin expression in >80% of transfected cells; top, white arrowheads) or Pax7 expression (not 
  depicted). β-Gal expression was used to identify transfected cells. Bar, 10 μm. (F) Pax7 protein stability is regulated during commitment to terminal differentiation. 
Mitotically synchronized MM14 cells were induced to differentiate for 15 h and treated with MG132 for 6 h before ﬁ  xation. In control conditions (DMSO), 
myogenin (88.9 ± 5.8%) and Pax7 (16.1 ± 6%) are expressed in a mutually exclusive pattern (top and middle, white arrows). Upon MG132 treatment, 
77.5 ± 10.1% of the cells are myogenin
+, yet 57.2 ± 13% of the cells are also Pax7
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At this time point (21 h after differentiation induction), >85% 
of the control cells expressed myogenin, whereas  15% of the 
cells expressed Pax7 in a mutually exclusive pattern (Fig. 4 F). 
After MG132 treatment, the percentage of Pax7
+ cells increased 
to  60%, whereas the percentage of myogenin
+ cells remained 
at  80% (Fig. 4 F). Under these conditions, myogenin and 
Pax7 were coexpressed in  50% of the cells analyzed (Fig. 4 F). 
Together, these results indicate that proteasome-dependent deg-
radation appears to play an important role in the loss of Pax7 
during myoblast commitment to terminal differentiation, cor-
relating with the expression and accumulation of myogenin.
Indirect protein–protein interaction 
between Pax7 and MyoD
Our fi  ndings suggest a reciprocal regulation between Pax7/MyoD 
and Pax7/myogenin during the progression of cell differentia-
tion. We asked whether these observations refl  ected interactions 
at the protein level by attempting copurifi  cation of Pax7–MyoD 
complexes or Pax7–myogenin complexes from nuclear extracts. 
Preliminary data indicated that putative Pax7–MyoD (and Pax7–
myogenin) interaction was transient and/or unstable in adult pri-
mary myoblasts cultures and in MM14 cells (unpublished data). 
Thus, we asked whether these complexes could be detected in 
C3H10T1/2 cells coexpressing myc-tagged Pax7 and MyoD. 
Under control differentiation conditions, little if any detect-
able MyoD coimmunoprecipitated with Pax7 (Fig. 5 A, lane 2), 
yet MyoD was readily detectable in immunoprecipitates from 
MG132-treated cells (Fig. 5 A, lane 3). We could not detect any 
signifi  cant copurifi  cation of MyoD and Pax7 under proliferation 
conditions (unpublished data). We were unable to detect any spe-
cifi  c Pax7–myogenin interactions using the same copurifi  cation 
strategy as for MyoD and Pax7 complexes (unpublished data). 
This could be explained by the strong effect on protein stability 
observed when both myogenin and Pax7 are coexpressed and thus 
may refl  ect a transient interaction disrupted during isolation.
Our previous results (Fig. 1, C and D) and the apparently 
weak Pax7–MyoD physical interaction, suggest that Pax7 and 
MyoD coexist in protein complexes through indirect interactions. 
This idea is further supported by the observation that these pro-
teins do not interact directly during in vitro coimmunoprecipitation 
assays (Fig. 5 B). Similarly, we cannot detect a direct interaction 
between Pax7 and myogenin (Fig. 5 B). Together, these data sug-
gest that upon external stimuli, Pax7 and members of the MRF 
family (i.e., MyoD and myogenin) can interact with common el-
ements in a protein complex, leading to functional inhibition and 
changes in protein stability perhaps by altering interactions 
within the protein complexes.
Discussion
The transcription factor Pax7 has been implicated in satellite 
cell specifi  cation, survival, and self-renewal (Seale et al., 2000; 
Olguin and Olwin, 2004; Oustanina et al., 2004; Zammit et al., 
2004; Kuang et al., 2006; Shinin et al., 2006). Although expres-
sion profi  les and genetic evidence suggest a functional inter-
action between Pax7 and the MRFs, this interaction has not been 
defi  ned at the molecular level. We have previously shown that 
Pax7 overexpression represses myogenesis (Olguin and Olwin, 
2004). Here, we attempted to delineate some of the molecular 
mechanisms responsible for these effects and the functional in-
teractions between Pax7 and the MRFs.
A Pax7–MRF mutually inhibitory circuit 
for satellite cell fate regulation
Muscle satellite cells, normally residing in a quiescent state, 
must be activated, proliferate, differentiate, and self-renew to 
maintain and repair adult skeletal muscle tissue. The mechanisms 
involved in regulating these decisions are not well understood. 
Here, we show evidence for an inhibitory regulatory relation-
ship between Pax7, MyoD, and myogenin that may play a role 
in determining the cell fate decisions of activated satellite cells 
(Fig. 6). We propose a working model where, upon satellite cell 
activation, MyoD is induced and the Pax7/MyoD ratio plays 
a critical role in cell fate determination. At low Pax7/MyoD 
  ratios, cells commit to terminal differentiation and induce myo-
genin, causing a rapid loss of Pax7. Intermediate Pax7/MyoD 
ratios prevent myogenin induction and may favor proliferation/
survival of committed cells. A small population of muscle pro-
genitors acquires or maintains a higher Pax7/MyoD ratio, causing 
a loss of MyoD protein, and may renew the quiescent satellite 
cell. In our model, the Pax7/MRF expression ratio is likely reg-
ulated via extracellular signaling and could integrate with addi-
tional external cues to promote commitment to each of these 
different cell fates (Fig. 6).
MyoD as a nodal point for Pax7 regulation 
of myogenesis
We initially hypothesized that Pax7 would inhibit myogenesis 
via a transcriptional mechanism that regulated MyoD activity 
Figure 5.  Indirect interaction between Pax7 and MRF proteins. (A) Nuclear 
fractions isolated from C3H10T1/2 cells transfected with MyoD alone or 
MyoD/myc–NLS-Pax7 (1:1 ratio) and induced to differentiate were immuno-
precipitated with an anti-myc antibody and further analyzed by Western 
blot for MyoD in the eluted fractions. There is a minimal increase in MyoD 
signal upon Pax7 coexpression (compare lanes 1 and 2) that is substantially 
increased (more than sevenfold) in the presence of MG132 (compare lanes 
1 and 3). (B) 
35S-labeled MyoD, myc–NLS-Pax7 (FL-Pax7), and myogenin (left) 
were combined as indicated and subjected to in vitro coimmunoprecipita-
tion (see Materials and methods) using anti–myc tag antibody. No MyoD–Pax7 
or myogenin–Pax7 interactions were detected (lanes 1 and 2, respectively). 
Arrowheads indicate expected Pax7, MyoD, and E47 bands in the TNT assay, 
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to prevent myogenin induction. Thus, we evaluated the inhi-
bitory effects of Pax7 on MyoD- and myogenin-dependent 
transcriptional activities in the context of a common target 
promoter. We found that MyoD activity was inhibited by Pax7 
but that myogenin-dependent transcription was only margin-
ally affected. Moreover, we have shown that under conditions 
where MyoD activity is enhanced, myogenin is up-regulated, 
promoting terminal differentiation even in the presence of ectopic 
Pax7 (Olguin and Olwin, 2004). These observations support the 
idea that once myogenin accumulates, Pax7 is incapable of pre-
venting muscle differentiation, in agreement with our working 
model (Fig. 6).
In a recent report, Zammit et al. (2006) showed that retro-
virus-mediated delivery of Pax7 does not prevent progression 
through myogenesis in myoblasts cultures. Because we postulate 
that timing, as well as the level of Pax7 expression, is critical for 
satellite cell fate decisions, these observations do not necessar-
ily disagree with our own. If Pax7 is expressed after myogenin 
induction, myoblasts will commit to terminal differentiation 
(Fig. 6). In agreement with our data on C3H10T1/2 cells, which 
lack endogenous Pax7 expression, Zammit et al. (2006) show that 
ectopic expression of Pax7 in a Pax7-null subclone of C2C12 
cells perturbs myogenic differentiation.
Genetic interactions indicate that Pax7 could participate 
in induction of the myogenic program during development 
(Ben-Yair and Kalcheim, 2005; Gros et al., 2005; Kassar-Duchossoy 
et al., 2005; Relaix et al., 2005). Moreover, ectopic expression 
of dominant-repressor Pax7 constructs (Pax7-EnR) suggests that 
Pax7-dependent transcription could induce MyoD expression 
(Chen et al., 2006; Relaix et al., 2006). In this context, our ob-
servations suggest that Pax7 may have a dual role where it acti-
vates the myogenic program by regulating MyoD transcription 
and prevents commitment to differentiation by regulating 
MyoD function, similar to what has been shown for Pax3 
function in melanocyte development (Lang et al., 2005). Anal-
ysis of gene expression profi  les from rhabdomyosarcoma cell 
lines overexpressing Pax-FKHR proteins (both Pax7- or Pax3-
FKHR) shows that MyoD expression is twofold higher than in 
controls; however, several genes related to muscle differentia-
tion (including myogenin) are specifi  cally down-regulated 
(Davicioni et al., 2006). These data further support the idea 
that by differentially regulating MyoD expression and func-
tion, Pax7 (or Pax-FKHR) may promote retention of muscle 
progenitor characteristics.
Transcriptional versus nontranscriptional 
regulation of MyoD activity by Pax7
Intriguingly, we showed that altering MyoD DNA binding 
specifi  city did not affect the ability of Pax7 to inhibit MyoD-
dependent transcription. Moreover, the binding of MyoD to 
DNA is not affected by Pax7 protein in vitro. Therefore, inhibi-
tion of MyoD activity by Pax7 does not appear to require com-
petitive binding to common DNA targets, suggesting that Pax7 
could function to either regulate transcription of additional 
genes required for MyoD function or via a nontranscriptional 
mechanism, such as posttranslational control of MyoD and/or 
MyoD protein interactions.
Pax7 and Pax3 contain all the major functional domains 
described for the Pax family, and this sequence/structural com-
plexity is thought to be refl  ected in an increased repertoire of 
targets and mechanisms for their own regulation (Chi and 
Epstein, 2002; Robson et al., 2006). Unlike Pax3, Pax7 is a 
poor transcriptional activator, containing two cis-acting re-
pressor domains (at the N terminus and the homeodomain, 
  respectively) (Bennicelli et al., 1999). Hence, we addressed the 
contribution of Pax7-dependent transcription on MyoD inhi-
bition by disrupting Pax7 domains thought to be critical for 
its transcriptional activity. Our data show that Pax7 represses 
myogenesis in the absence of either its paired-box or the trans-
activation domains, whereas deletion of the homeodomain ab-
rogates the ability of Pax7 to inhibit myogenesis. Moreover, 
expression of the C-terminal Pax7 region, including the homeo-
domain and the transactivation domain, is suffi  cient to repress 
MyoD activity in C3H10T1/2 cells. As expected, deletion of 
either the paired-box domain or the transactivation domain 
abolishes Pax7-dependent transcription of a Pax3/Pax7-specifi  c 
reporter gene.
Remarkably, Pax7-dependent transcriptional activation ap-
pears to be highly dependent on the cellular context. Although 
we detected activity from the full-length Pax7 in differentiation 
media, the activation was modest and only twofold above back-
ground. In contrast, we observed robust activation of the Pax7 
reporter in cells maintained in proliferation media. Moreover, 
the ∆HD mutant was transcriptionally active under both condi-
tions, yet this mutant fails to repress MyoD activity. These re-
sults contrast directly with recent observations where ectopically 
expressed Pax7 sustains transcription during myoblast differen-
tiation (Zammit et al., 2006). In this study, the construct used 
for generation of a reporter mouse strain contained only binding 
Figure 6.  Working model: reciprocal regulation of Pax7 and MRFs dur-
ing myogenic cell fate commitment. Satellite cells (Pax7
+/MyoD
−/myo-
genin
−) must commit to proliferate, differentiate, or renew the progenitor 
population to maintain muscle function. We propose that commitment to 
proliferate requires environmental cues (gray arrows) that activate satellite 
cells and up-regulate MyoD (blue) with a concomitant decline in Pax7 
expression (green). Upon commitment to terminal differentiation, up-regulation 
of myogenin (red) down-regulates Pax7. In a small cell population, up-
regulation of myogenin is prevented; Pax7 is up-regulated by unknown 
mechanisms, resulting in MyoD down-regulation (green nucleus and 
dashed cytoplasm cell) leading to the commitment to a quiescent, undiffer-
entiated phenotype. In this model, the Pax7/MRF expression ratio is critical 
and integrates with environmental signals (gray arrows) to regulate cell 
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sites for the paired-box domain (derived from the Trp-1 gene) to 
drive the expression of β-galactosidase. The reporter gene used 
in the present study contains binding sites for both the paired-
box domain and the homeodomain (derived from the e5 se-
quence in the Drosophila even-skipped promoter) to drive the 
expression of luciferase. Thus, differences in Pax7-dependent 
transcription appear to be cell type, cell context, and reporter 
context dependent. Nevertheless, our fi  ndings strongly suggest 
that Pax7 transcriptional activity is not directly involved in the 
inhibition of MyoD. We envision that Pax7 acts in part via 
protein–protein interactions that may disrupt functional MyoD-
containing transcriptional complexes, resulting in loss of spe-
cifi  c MyoD functions and inhibition of myogenesis. In agreement 
with this idea, we showed that MyoD protein levels are reduced 
upon ectopic expression of Pax7. Importantly, the loss of MyoD 
protein requires the Pax7 homeodomain and can be reverted by 
inhibition of proteasome activity.
Proteasome-dependent MyoD degradation is inhibited by 
MyoD binding to DNA in vitro (Abu Hatoum et al., 1998). 
Interestingly, we showed that although proteasome inhibition 
rescued MyoD protein levels, its myogenic function was not 
restored, further supporting the idea that MyoD-containing 
complexes may be disrupted by Pax7. Although we can detect 
complexes containing both MyoD and Pax7 consistently in the 
presence of proteasome inhibitors, we cannot detect interac-
tions between Pax7 and MyoD when purifi  ed proteins are used 
in gel shift assays or after in vitro coimmunoprecipitation. Thus, 
our data suggest that Pax7 and MyoD coexist in a protein com-
plex through indirect interactions. Pax7 has also been found in 
a complex with MyoD by mass spectrometry, using alternative 
cellular sources (unpublished data), supporting the existence of 
a protein complex containing Pax7 and MyoD. In addition, our 
results do not rule out an effect of Pax7 on transcription of co-
factors required for MyoD function, via inhibitory protein–
protein interactions at specifi  c promoters. Current efforts are 
directed to the development of tools for the unbiased identifi  ca-
tion of Pax7-interacting partners in myogenic cells.
Commitment to terminal muscle 
differentiation and the regulation 
of Pax7 expression
Pax7 and myogenin expression in individual cells occurs in a 
mutually exclusive pattern (Olguin and Olwin, 2004; Zammit 
et al., 2004). Prompted by the observation that ectopic co-
expression of Pax7 and myogenin results in decreased levels of 
both proteins in C3H10T1/2 cells, we analyzed the expression 
of myogenin and Pax7 during commitment to differentiation in 
mitotically synchronized MM14 myoblasts. During differen-
tiation, Pax7 and myogenin transiently coexist in the same cell 
population, but as differentiation progresses and myogenin lev-
els increase, Pax7 levels decline, exhibiting the mutually exclu-
sive expression pattern described previously. Interestingly, the 
time at which Pax7 levels decline correlates with the irreversible 
commitment of MM14 cells to terminal differentiation (Clegg 
et al., 1987). At this time point, it is already possible to iden-
tify a minor population of Pax7
+/myogenin
− cells that remains 
throughout differentiation, reminiscent of the reserve population 
phenotype (Yoshida et al., 1998; Olguin and Olwin, 2004). 
Conversely, the loss of Pax7 expression correlates with the loss 
of the Pax7
+/myogenin
+ phenotype, suggesting that during this 
period, myogenin expression down-regulates Pax7. Using a sim-
ilar strategy used to detect Pax7- and MyoD-containing protein 
complexes, we were unable to detect Pax7–myogenin inter-
actions. If a Pax7–myogenin complex exists, it may be too weak 
to be detected by these methods. Alternatively, the lack of a detect-
able interaction could be due to the observations that Pax7 and 
myogenin appear unstable when both proteins are present. In 
summary, these fi  ndings are compatible with a model whereby 
myogenin up-regulation results in the rapid loss of Pax7 during 
myoblast differentiation, and inhibition of myogenin expression 
may be necessary for maintenance and up-regulation of Pax7 
in activated satellite cells that escape differentiation, eventually 
contributing to satellite cell self-renewal.
Materials and methods
Cell lines
C3H10T1/2 cells were cultured in DME and 10% fetal bovine serum at 
37°C and 5% CO2. For myogenic conversion assays, cultures were induced 
to differentiate in DME and 2% fetal bovine serum for 48 h or as speciﬁ  ed. 
MM14 cells were cultured in F12-C, 15% horse serum, and 500 pM FGF-2 
at 37°C and 5% CO2. Differentiation was induced by culture in F12-C and 
10% horse serum. When speciﬁ   ed, cells were treated with 20–25 μM 
MG132 (Calbiochem) for 6–8 h before harvesting or ﬁ  xation.
Pax7-deletion mutants
Pax7 deletions were constructed via PCR mutagenesis using pcDNA-Pax7d 
vector (Olguin and Olwin, 2004) as a template. Appropriate restriction 
sites were included at the 5′-end of forward and reverse primers (Table I). 
Pax7 (and mutant) cDNAs were subcloned into pcDNA3-myc-NLS ex-
pression vector (BamHI and XhoI sites; a gift from J. Lykke-Andersen and 
G. Singh, University of Colorado, Boulder, CO). In frame cloning introduces 
a single copy of a myc-tag epitope followed by the SV40 T-antigen NLS, 
to the 5′-end of each cloned cDNA.
Myogenic conversion and reporter assays
Myogenic conversion of C3H10T1/2 cells was induced by transfecting 
(Superfect; QIAGEN) 1 μg/well (12-well plate) of the pRSV-MyoD vector. 
Differentiation was induced 24 h after transfection for 24 or 48 h as indi-
cated. When required, pcDNA-Pax7 vector was cotransfected along with 
pRSV-MyoD or pEMS-ratmyogenin vectors at the indicated molar ratios. 
pcDNA3 was used as control DNA. To evaluate MyoD transcriptional 
activity, 1 μg of the myogenin-luc reporter gene was transfected in the 
absence or the presence of 0.4 μg pRSV-MyoD and in the absence or 
presence of pcDNA-Pax7 (at the speciﬁ  ed molar ratios), in triplicate for 
each condition. 0.025 μg of the CMV-LacZ expression vector was cotrans-
fected as a marker for transfection efﬁ  ciency, and pcDNA3 was used as 
control DNA. After differentiation induction, whole cell lysates were col-
lected and luciferase and β-galactosidase activities were determined using 
the Dual-Light System (Applied Biosystems) as reported previously (Olguin 
and Olwin, 2004). Total protein content was estimated (micro BCA; Pierce 
Chemical Co.) for subsequent analyses. Where indicated, the fold differ-
ence between maximum activation (reporter plus MyoD or myogenin ex-
pression vector) and the activation in different experimental conditions was 
represented as fold repression.
C3H10T1/2 cells were cotransfected with Gal4-luc reporter gene 
and either Gal4-MyoD or Gal4-VP16 fusion proteins in the presence or the 
absence of pCDNA3-Pax7 at the indicated molar ratios. Pax7 and Pax7-
deletion mutants were tested for transcriptional activation in C3H10T1/2 
cells as described above by cotransfection with the 6xPRS9-Luc reporter 
gene (provided by F. Barr, University of Pennsylvania, Philadelphia, PA), in 
the presence or absence of MyoD.
In vivo and in vitro coimmunoprecipitation
For in vivo coimmunoprecipitation experiments, C3H10T1/2 cells were 
transiently transfected with 1:1 molar ratio (MyoD/myc-Pax7), as described JCB • VOLUME 177 • NUMBER 5 • 2007  778
previously. When indicated, cells were incubated with 20 μM MG132 for 
6 h before harvest. Cells were washed twice and harvested in ice-cold PBS 
using a cell scraper. Cell pellet was recovered by centrifugation and resus-
pended in 1 ml buffer A (10 mM Hepes, pH 7.6, 1.5 mM MgCl2, 10 mM 
KCl, and 0.5 mM DTT). After a 10-min incubation in ice, cell pellet was re-
covered, resuspended in 400 μl buffer A, and disrupted in ice using a 
Dounce tissue grinder. Cell nuclei were recovered by centrifugation and re-
suspended in 200 μl buffer B (20 mM Hepes, pH 7.6, 0.5 mM EDTA, 100 mM 
KCl, 10% glycerol, 2 mM DTT, 3 mM CaCl2, 1.5 mM MgCl2, 0.25 mM 
Na3VO4, 1 mM NaF, 50 mM β-glycerophosphate, and protease inhibitor 
cocktail). Nuclear fraction was treated with nuclease S7 (Roche; 6 mU/μg 
of total DNA) for 10 min at 37°C. Nuclease activity was stopped by addi-
tion of EDTA (20 mM ﬁ  nal concentration), and nuclear fraction was incu-
bated for 2 h at 4°C with gentle rotation. Extracts were recovered by 
centrifugation. For immunoprecipitation, total protein was equalized ( 200 μl 
at 1 mg/ml), precleared with 20 μl of agarose–protein G (50% slurry; 
Pierce Chemical Co.), and incubated in the presence or absence of anti–
myc tag antibody (clone 9B11 at a dilution of 1:1,000; Cell Signaling) at 
4°C overnight. Immunocomplexes were captured by incubation with agarose–
protein G for 3 h at 4°C, washed ﬁ  ve times for 5 min each in buffer B, and 
eluted by resuspending beads in 50 μl 2× SDS-PAGE loading buffer and 
boiling for 5 min.
For in vitro coimmunoprecipitation experiments, 
35S-labeled proteins 
were obtained by coupled transcription and translation in rabbit reticulo-
cyte lysate (Promega). Protein interaction and immunopuriﬁ  cation (using 
equivalent protein concentration estimated by autoradiography) was per-
formed as described by Davis et al. (1990) using anti–myc tag antibody. 
Proteins were visualized by SDS-PAGE and autoradiography (Storm 860 
Scanner [Molecular Dynamics]; control software version 5.03).
EMSAs
Gel mobility shift assays were performed from rabbit reticulocyte translated 
proteins (Davis et al., 1990) or puriﬁ  ed proteins (Thayer and Weintraub, 
1993) as required. Approximately equal amounts of each factor were 
added to the binding reactions (estimated by 
35S-methionine incorporation 
in a translation reaction performed in parallel).
Myogenin overexpression and knockdown
pEMS-ratmyogenin (1.5 μg/well; 6-well plate) was used to ectopically ex-
press myogenin in MM14 cells and adult primary myoblasts (Lipofectamine 
2000; Invitrogen). Cells were ﬁ  xed and subjected to immunoﬂ  uorescence 
staining 24 h after transfection. For myogenin expression knockdown, 200 nM 
SMARTpool siRNA duplexes (Dharmacon) were transfected in MM14 cells 
(Transmessenger; QIAGEN). siCONTROL RISC-free siRNA (Dharmacon) 
was used as a negative control. Cells were ﬁ  xed 48–72 h after trans-
fection. Speciﬁ  c and control siRNA duplexes were provided by Y. Fedorov 
(Dharmacon, Lafayette, CO).
Western blotting
Whole C3H10T1/2 cell extracts were obtained by disruption in modiﬁ  ed 
RIPA lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% IGEPAL, 
1 mM NaFl, 1 mM Na3Vo4, and 1× Complete anti-protease cocktail 
[Roche]), and incubating for 10 min at 4°C. Lysates were cleared by 
centrifugation. 30–50 μg total protein were loaded onto 10% SDS-PAGE 
gels and transferred onto polyvinylidene diﬂ  uoride membranes (Millipore). 
Primary antibodies and dilutions used were as follows: mouse monoclonal 
anti-MyoD1 (clone 5.8A; Vector Laboratories) at 1:100; mouse mono-
clonal anti-Pax7 (Developmental Studies Hybridoma Bank) at 1:10 (cell cul-
ture supernatant); mouse monoclonal anti-myogenin (F5D; Developmental 
Studies Hybridoma Bank) at 1:10 (cell culture supernatant); mouse mono-
clonal anti–α-tubulin (DM1A; Sigma-Aldrich) at 1:100; mouse monoclonal 
anti–myc tag (9B11; Cell Signaling) at 1:1,000. Anti-mouse HRP-conjugated 
secondary antibodies (Promega) were used at 1:5,000, and HRP activity 
was visualized using the ECL Plus Western Blotting Detection System (GE 
Healthcare). When required, x-ray ﬁ  lms were scanned (Powerlook 1120 
scanner; UMAX), digitalized (VueScan 7.6.8; Hamrick Software), and 
analyzed (ImageJ; NIH) for ﬁ  gure preparation.
Immunoﬂ  uorescence
Cells were ﬁ  xed in 4% paraformaldehyde for 20 min. Primary antibodies 
and dilutions used were as follows: mouse monoclonal anti-Pax7 (Devel-
opmental Studies Hybridoma Bank) at 1:5 (cell culture supernatant); rab-
bit polyclonal anti-MyoD (Santa Cruz Biotechnology, Inc.) at 1:30; rabbit 
polyclonal anti-myogenin (Santa Cruz Biotechnology, Inc.) at 1:30; mouse 
monoclonal anti-MyHC (MF20; Developmental Studies Hybridoma Bank) 
at 1:5 (cell culture supernatant). Secondary antibodies conjugated to 
Alexa 594 or Alexa 488 were obtained from Invitrogen. Vectashield 
(Vector Laboratories) was used as mounting media. Micrographs were 
taken from an epiﬂ  uorescence microscope (Eclipse E800 [Nikon] using 
20×/0.50 and 40×/0.75 objectives [Nikon]) at RT, using Slidebook 
v3.0 acquisition software (Intelligent Imaging Innovations, Inc.) coupled 
to a digital camera (Sensicam; Cooke). Digital deconvolution for single 
plane images (no neighbors) was applied (when required) to acquired 
images (Slidebook v3.0).
Image processing and ﬁ  gure preparation
For ﬁ  gure preparation, images were exported into Photoshop (Adobe). If 
necessary, the brightness and contrast were adjusted to the entire image, the 
image was cropped, and individual color channels were extracted (when 
required) without color correction adjustments or γ adjustments. Final ﬁ  gures 
were prepared in PowerPoint (Microsoft) and Illustrator (Adobe).
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Table I. Primers and cDNA products for construction of Pax7-deletion mutants
cDNA Forward primer (5′®3′)/target location (nt) Reverse primer (5′®3′)/target location (nt)
FL G  G  A  T  C  C  A  T  G  G  C  G  G  C  C  C  T  T  C  C  C  /1–15 C  T  C  G  A  G  C  T  A  G  T  A  G  G  C  T  T  G  T  C  C  C  G  T  T  T  C  C  A  C  /1489–1512
∆NG   G  A  T  C  C  G  G  G  A  A  G  A  A  A  G  A  G  G  A  C  G  A  C  G  A  G  /487–507 C  T  C  G  A  G  C  T  A  G  T  A  G  G  C  T  T  G  T  C  C  C  G  T  T  T  C  C  A  C  /1489–1512
∆CG   G  A  T  C  C  A  T  G  G  C  G  G  C  C  C  T  T  C  C  C  /1–15 C  T  C  G  A  G  C  T  A  T  C  C  T  G  C  C  T  G  C  T  T  G  C  G  C  C  A  /811–828
∆HD
 N-Pax7
a G  G  A  T  C  C  A  T  G  G  C  G  G  C  C  C  T  T  C  C  C  /1–15 C  T  G  G  T  T  A  G  C  G  C  G  C  T  G  C  T  T  G  C  G  C  T  T  C  A  G  /631–648
 C-Pax7
b A  A  G  C  A  G  C  G  C  G  C  T  A  A  C  C  A  G  C  T  G  G  C  C  G  C  C  /826–843 C  T  C  G  A  G  C  T  A  G  T  A  G  G  C  T  T  G  T  C  C  C  G  T  T  T  C  C  A  C  /1489–1512
  ∆HD
c G  G  A  T  C  C  A  T  G  G  C  G  G  C  C  C  T  T  C  C  C  /1–15 C  T  C  G  A  G  C  T  A  G  T  A  G  G  C  T  T  G  T  C  C  C  G  T  T  T  C  C  A  C  /1489–1512
∆NO G  G  A  T  C  C  C  A  G  C  G  C  C  G  C  A  G  T  C  G  G  A  C  C  /643–660 C  T  C  G  A  G  C  T  A  G  T  A  G  G  C  T  T  G  T  C  C  C  G  T  T  T  C  C  A  C  /1489–1512
∆NHD G  G  A  T  C  C  G  C  T  A  A  C  C  A  G  C  T  G  G  C  C  G  C  C  /826–843 C  T  C  G  A  G  C  T  A  G  T  A  G  G  C  T  T  G  T  C  C  C  G  T  T  T  C  C  A  C  /1489–1512
GGATCC, BamHI recognition site; CTCGAG, XhoI recognition site.
aN terminus/paired box/octapeptide.
bTransactivation domain.
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